|
|
| | Evolocumab Basic information |
| Product Name: | Evolocumab | | Synonyms: | Evolocumab;AMG 145;Research Grade Evolocumab(DHJ24002);AMG-145,Ser/Thr Protease,Repatha,AMG 145,inhibit,atherosclerotic cardiovascular disease,Serine endopeptidases,PCSK9,Evolocumab,AMG145,Threonine proteases,hypercholesterolemia,LDLR,Inhibitor,Serine proteases;Evolocumab(anti-PCSK9) | | CAS: | 1256937-27-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Evolocumab Structure]() |
| | Evolocumab Chemical Properties |
| storage temp. | Store at 4°C, protect from light |
| | Evolocumab Usage And Synthesis |
| Clinical Use | IgG2 monoclonal antibody:Treatment of hypercholesterolaemia, mixed
dyslipidaemia and homozygous familial
hypercholesterolaemia | | Drug interactions | Potentially hazardous interactions with other drugs
Antipsychotics: avoid with clozapine - increased risk
of agranulocytosis.
Vaccines: avoid concomitant use with live vaccines. | | Metabolism | Evolocumab is composed of amino acids and
carbohydrates as native immunoglobulin and is unlikely
to be eliminated via hepatic metabolic mechanisms.
Its metabolism and elimination are expected to follow
the immunoglobulin clearance pathways, resulting in
degradation to small peptides and individual amino acids. |
| | Evolocumab Preparation Products And Raw materials |
|